INT68228

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 1997
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 9
Disease Relevance 6.26
Pain Relevance 0.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (TNFRSF8) plasma membrane (TNFRSF8) cytoplasm (TNFRSF8)
Anatomy Link Frequency
plasma 1
CCRF-CEM 1
B-cell 1
TNFRSF8 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 41 97.68 Very High Very High Very High
rheumatoid arthritis 5 96.68 Very High Very High Very High
Inflammatory response 5 95.60 Very High Very High Very High
Pain 4 82.16 Quite High
agonist 5 79.64 Quite High
member 8 10 51.48 Quite High
cytokine 15 50.00 Quite Low
headache 2 5.00 Very Low Very Low Very Low
Paresthesia 1 5.00 Very Low Very Low Very Low
fifth nerve 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diffuse Large B-cell Lymphoma 1 99.90 Very High Very High Very High
Infection 11 99.84 Very High Very High Very High
Viral Infection 15 99.44 Very High Very High Very High
Autoimmune Disease 5 99.40 Very High Very High Very High
Disease 15 99.30 Very High Very High Very High
Hypersensitivity 7 98.72 Very High Very High Very High
Cancer 35 98.32 Very High Very High Very High
Systemic Lupus Erythematosus 5 97.88 Very High Very High Very High
INFLAMMATION 45 97.68 Very High Very High Very High
Lymphatic System Cancer 37 97.58 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Similar to serum Trx1, serum sCD30 is increased in infection, autoimmunity and allergy, for example systemic lupus erythematosus, rheumatoid arthritis and atopic dermatitis (Horie and Watanabe, 1998).
Positive_regulation (increased) of sCD30 associated with autoimmune disease, hypersensitivity, rheumatoid arthritis, eczema, systemic lupus erythematosus and infection
1) Confidence 0.56 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 1.09 Pain Relevance 0.16
Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fc(gamma)-receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen, respectively.
Positive_regulation (directed) of CD30 associated with disease
2) Confidence 0.49 Published 1997 Journal Blood Section Abstract Doc Link 9058726 Disease Relevance 0.42 Pain Relevance 0.06
A group of 15 patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural-killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fc gamma receptor III (CD16 antigen) and the Hodgkin's associated CD30 antigen.
Positive_regulation (directed) of CD30 associated with disease
3) Confidence 0.49 Published 1997 Journal Cancer Immunol. Immunother. Section Abstract Doc Link 9435869 Disease Relevance 0.42 Pain Relevance 0.08
Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II dose escalation trial with the NK-cell activating bispecific monoclonal antibody HRS-3/A9 which is directed against the Fcgamma-receptor III (CD16 antigen) and the Hodgkin's associated CD30 antigen, respectively.
Positive_regulation (directed) of CD30 associated with disease
4) Confidence 0.49 Published 1998 Journal Leuk. Lymphoma Section Abstract Doc Link 9869203 Disease Relevance 0.39 Pain Relevance 0.07
Consistent with previous results (Bowen et al, 1993), we observed that stimulation of CD30 with either agonistic antibodies or sCD30L led to upregulation of the IL-2R?
Positive_regulation (stimulation) of CD30
5) Confidence 0.46 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.14 Pain Relevance 0.04
In vivo activation of CD30 can be monitored by the release of sCD30, shed from the plasma membrane upon CD30L binding (Hansen et al, 2000).
Positive_regulation (activation) of CD30 in plasma
6) Confidence 0.46 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.92 Pain Relevance 0.12
Elevated levels of sCD30 occur during viral infection.
Positive_regulation (levels) of sCD30 associated with viral infection
7) Confidence 0.43 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 1.11 Pain Relevance 0.21
While Hodgkin's disease cell lines typically express high levels of CD30, other cell lines including LCL-721.220 or CCRF-CEM show at least 20- to 100-fold lower expression as determined by flow cytometry, yet the same selective targeting was observed.
Positive_regulation (levels) of CD30 in CCRF-CEM associated with disease
8) Confidence 0.43 Published 2007 Journal EMBO J Section Body Doc Link PMC1914094 Disease Relevance 0.10 Pain Relevance 0.05
In contrast to HS, diffuse large B-cell lymphoma constantly express various pan-B markers such as CD19, CD20, CD22, and CD79a, while anaplastic large cell lymphomas are positive for CD30, and ALK [1].
Positive_regulation (positive) of CD30 in B-cell associated with lymphatic system cancer, histiocytic sarcoma and diffuse large b-cell lymphoma
9) Confidence 0.14 Published 2007 Journal Diagn Pathol Section Body Doc Link PMC1808440 Disease Relevance 1.67 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox